W
WAVEMAN · COMPANY
MAZE · Maze Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

MAZE

Maze Therapeutics, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001842295
FORM 144 · 10☆ WATCH
INSIDER NET · 180D
-$10.5M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
106
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-78.3%
CONVERSIONS · 180D
17
codes C/M, not in net · $1.9M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$10.5M over 180 days
-$5.3M over 90 days
below 85% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
106 funds added or opened last quarter
more than 68% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
-78.3% net margin
below 62% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
10.2% of shares outstanding short · 15.9 days to cover · settled 2026-07-31
more than 77% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$10.5M across 5 people in 180 days.
106 funds added or opened positions in the latest 13F quarter, of 164 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +71.1%
+71.1%12M
-2%+78%+158%+238%2025-092025-102025-122026-032026-052026-072026-09 2025-12-29 · Dandekar Atul sold $2.7M2026-03-10 · Bernstein Harold sold $1.5M2025-12-29 · Bernstein Harold sold $1.1M2026-01-07 · Sohn Catherine A. sold $1.1M2026-01-07 · Bernstein Harold sold $1.0M2026-07-01 · Coloma Jason V sold $907.9K2026-08-03 · Coloma Jason V sold $809.5K2025-12-29 · Bernstein Harold sold $704.0K2026-05-26 · Coloma Jason V sold $665.6K2026-06-23 · Coloma Jason V sold $621.7K2025-09-15 · SCHELLER RICHARD H sold $464.0K2026-08-13 · Bernstein Harold sold $445.6K2026-07-01 · Bernstein Harold sold $400.5K2026-05-14 · Bernstein Harold sold $393.3K2026-02-02 · Bernstein Harold sold $383.8K2025-12-29 · Bachrodt Amy sold $381.1K2026-06-01 · Bernstein Harold sold $338.9K2026-04-01 · Bernstein Harold sold $331.9K2026-03-20 · Bernstein Harold sold $297.0K2026-09-03 · Coloma Jason V sold $293.5K2026-02-02 · Bernstein Harold sold $275.3K2026-09-02 · Coloma Jason V sold $259.9K2026-03-20 · Bernstein Harold sold $252.3K2025-12-29 · Dandekar Atul sold $248.2K2026-01-22 · Bachrodt Amy sold $227.6K2026-06-29 · Dandekar Atul sold $210.2K2026-08-28 · Dandekar Atul sold $206.8K2025-12-30 · Bachrodt Amy sold $200.4K2026-05-29 · Dandekar Atul sold $197.6K2026-03-30 · Dandekar Atul sold $196.3K2026-07-29 · Dandekar Atul sold $193.9K2026-04-29 · Dandekar Atul sold $190.3K2026-03-20 · Bernstein Harold sold $187.2K2026-02-02 · Bachrodt Amy sold $187.1K2026-01-02 · Bernstein Harold sold $179.2K2026-02-27 · Dandekar Atul sold $172.0K2026-02-27 · Dandekar Atul sold $168.7K2026-03-02 · Bachrodt Amy sold $168.2K2026-06-01 · Coloma Jason V sold $159.6K2026-01-29 · Dandekar Atul sold $154.1K2026-09-03 · Bernstein Harold sold $133.4K2026-01-29 · Dandekar Atul sold $126.0K2026-09-04 · HAROLD BERNSTEIN filed to sell $251.1K2026-09-02 · Harold Bernstein filed to sell $283.5K2026-09-02 · Jason V Coloma filed to sell $623.4K2026-09-02 · Courtney Phillips filed to sell $110.0K2026-09-02 · Atul Dandekar filed to sell $177.2K2026-09-01 · Coloma Jason V filed to sell $908.1K2026-08-03 · Coloma Jason V filed to sell $922.6K2026-07-29 · ATUL DANDEKAR filed to sell $627.3K2026-07-01 · HAROLD BERNSTEIN filed to sell $1.4M2026-07-01 · Coloma Jason V filed to sell $1.0M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $10.5M sold by insiders over 180 days, 106 funds added last quarter, $6.3M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Maze Therapeutics, Inc. insiders sold a net $10.5M of stock across 88 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Bernstein Harold
President, R&D & CMO
SELL
2026-09-03
5,130.0
$133.4K
Bernstein Harold
President, R&D & CMO
SELL
2026-09-03
59.0
$1.5K
Coloma Jason V
Chief Executive Officer
SELL
2026-09-03
11,282.0
$293.5K
Coloma Jason V
Chief Executive Officer
SELL
2026-09-03
129.0
$3.3K
Dandekar Atul
CSBO
SELL
2026-09-03
3,207.0
$83.4K
88 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 83 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Frazier Life Sciences Management, L.P.
5,032,915.0 sh
$150.2M
TRV GP IV, LLC
4,473,958.0 sh
$133.5M
ARCH Venture Management, LLC
4,120,053.0 sh
$123.0M
Deep Track Capital, LP
3,732,569.0 sh
$111.4M
BlackRock, Inc.
3,502,841.0 sh
$104.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
HAROLD BERNSTEIN
FILED 2026-09-04
$251.1K
Harold Bernstein
FILED 2026-09-02
$283.5K
Jason V Coloma
FILED 2026-09-02
$623.4K
Courtney Phillips
FILED 2026-09-02
$110.0K
Atul Dandekar
FILED 2026-09-02
$177.2K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
ALPS Medical Breakthroughs ETF
$2.0M POSITION · AS OF 2026-02-28
1.4%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$3.5M POSITION · AS OF 2026-03-31
1.1%
PROFUND VP PHARMACEUTICALS
$110.8K POSITION · AS OF 2026-03-31
1.1%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$90.9K POSITION · AS OF 2026-04-30
0.7%
Invesco Dorsey Wright Healthcare Momentum ETF
$613.1K POSITION · AS OF 2026-04-30
0.5%
Virtus Biotech Clinical Trials Etf
$188.8K POSITION · AS OF 2026-04-30
0.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
0 ACTIVE
2
Phase 2
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-12
REVENUE—$167.5M
OPERATING INCOME$-142.9M$57.6M
NET INCOME$-131.1M$52.2M
EPS (DILUTED)-3.051.25
OPERATING CASH FLOW$-111.9M$76.0M
CASH$189.2M$196.8M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →